Results 101 to 110 of about 3,726 (180)

Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database. [PDF]

Front Pharmacol
Wang S, Xu Y, Lin H, Zhang X, Ding J, Jiang H, Fan Y, Sun C.   +7 more
europepmc   +1 more source

Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania. [PDF]

Medicina (Kaunas)
Indrisiunaite E, Jonaityte IR, Karmaziene T, Raudonis T.   +3 more
europepmc   +1 more source

Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions. [PDF]

J Pers Med
Pool IA, Otten AT, Kosterink JGW, Dijkstra G, Mian P, Bourgonje AR.   +5 more
europepmc   +1 more source

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis). [PDF]

Dermatol Ther (Heidelb)
Trovato E, Cartocci A, Gaiani F, Messina F, Mastorino L, Macagno N, Carugno A, Campoli M, Fargnoli MC, Lora V, Rossi A, Gioacchini H, Potestio L, D'Agostino GM, Maurelli M, Girolomoni G, Romanelli M, Dini V, Loconsole F, Satolli F, Pagnanelli G, Lasagni C, Michelerio A, Dragotto M, Malagoli P, Zerbinati N, Orsini D, Campanati A, Megna M, Bianchelli T, Italian Landscape Group, Costanzo A, Ribero S, Narcisi A.   +33 more
europepmc   +1 more source

Guselkumab is effective in the treatment of Inverse psoriasis: a case report and literature review. [PDF]

Front Med (Lausanne)
Wu Z, Xie X, Tang W, Wu Y, Zhang G, Zhu Q.   +5 more
europepmc   +1 more source

Patient Satisfaction Using Guselkumab Self-administered Using the One-Press Device for Treatment of Moderate-to-Severe Psoriasis: Results from a National, Prospective, Real-World Study in Portugal (CERES Study). [PDF]

Dermatol Ther (Heidelb)
Torres T, Sousa JT, Antunes J, Mendes-Bastos P, Brasileiro A, Neto V, Henrique M, Pimenta R, Magina S, Lourenço D, Mota F.   +10 more
europepmc   +1 more source

Factors Predicting Guselkumab Treatment Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of Korean Real-World Data. [PDF]

J Clin Med
Lee YB, Shin BS, Kim M, Suh MK, Youn SW, Lee JY, Kim CW, Lee GY, Kim KH, An J, Kim Y, Kim KJ, Kim DH, Son SW.   +13 more
europepmc   +1 more source

IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far? [PDF]

J Inflamm Res
Megna M, D'Agostino M, Feo F, Ventura V, Tommasino N, Potestio L.   +5 more
europepmc   +1 more source

Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies-A Scoping Review. [PDF]

Life (Basel)
Athanassiou L, Kostoglou-Athanassiou I, Kaiafa G, Savopoulos C, Shoenfeld Y, Athanassiou P.   +5 more
europepmc   +1 more source

A 76-week real-world multidimensional analysis of guselkumab in moderate to severe plaque psoriasis: a retrospective cohort study based on Chinese clinical practice standards. [PDF]

Front Immunol
Hu R, Li Q, Liu X, Hu Y, Pan Y, Liu C, Lu P, Chen X, Xiong J, Zhang J, Huang K.   +10 more
europepmc   +1 more source